Leukotriene B4 receptor transgenic mice
AssigneeThe Brigham and Women's Hospital, Inc.
InventorCharles N. Serhan
Life of this patent
Estimating the term…
Abstract
The present invention describes a non-human transgenic mouse that produces in its leukocytes, a recombinant human leukotriene B4 receptor (BLTR), having physiological activity of human BLTR. The transgenic mouse has stably integrated into its genome an exogenous gene construct which includes (A) 5′ expression regulating sequences, including a BLTR specific promoter, (B) DNA encoding the BLTR and a signal sequence effective in directing overexpression of the BLTR into leukocytes of the transgenic mouse and (C) 3′ regulatory sequences that result in the overexpression of the DNA in the leukocytes. In one embodiment, (A), (B), and (C) are operably linked in the gene construct to obtain production of the BLTR in the leukocytes and overexpression thereof in the transgenic mouse.
Claims9
A transgenic mouse that produces in its leukocytes a recombinant human leukotriene B4 receptor (hBLTR), wherein said transgenic mouse has stably integrated into its genome an exogenous expression vector that comprises a nucleotide sequence comprising a CD11b promoter in operable linkage with a nucleotide sequence encoding said hBLTR, and wherein expression of said hBLTR results in an increased recruitment of polymorphonuclear neutrophils (PMN) in response to acute skin inflammation, peritonitis, or ischemia reperfusion injury, in said mouse.
Dependencies are inferred from the claim text.